Inherited BRCA mutations
- Medical Review: LBBC Staff
BRCA1 and BRCA2 are genes present in everyone’s body. When they function normally, they help control cell growth by repairing damaged DNA. Everyone inherits one copy of the BRCA1 and BRCA2 genes from each parent.
Sometimes, BRCA1 and BRCA2 genes can develop changes called mutations that increase the risk of breast, ovarian, and other cancers. BRCA1 and BRCA2 mutations can be passed on from a parent.
Below, we discuss BRCA mutations and what testing positive or negative for a mutation means for your treatment, for reducing the risk of future cancers, and for your family.
If you have never been diagnosed with breast cancer and are concerned about your risk, visit At high risk for breast cancer to learn more.
What are inherited BRCA mutations?
BRCA1 and BRCA2 are the genes most commonly linked to hereditary breast cancer. They also increase the risk of:
- Breast cancer developing in the opposite breast
- Ovarian cancer
BRCA mutations are passed down from a parent. If either of your parents has a BRCA mutation, you have a 50% chance of having it, too.
In the United States, about one in 400 people have a harmful BRCA mutation. In some groups of people, the risk of having a mutation may be higher. For example, if you come from an Ashkenazi Jewish background (your family is Jewish and comes from Eastern or Central Europe), your risk is around one in 40.
In the United States, a woman’s average risk of breast cancer is about 13%. Men have close to a 0.1% risk. Carrying a BRCA1 or BRCA2 mutation raises this risk.
- Women who carry a BRCA1 or BRCA2 mutation have a greater than 60% risk of developing breast cancer in their lifetime.
- Men who carry a BRCA1 mutation have a 0.2% to 1.2% risk of developing breast cancer in their lifetime.
- Men who carry a BRCA2 mutation have a 2%-7% risk of developing breast cancer in their lifetime.
Having a BRCA mutation also raises the risk of ovarian cancer.
- BRCA1 mutation carriers have a 39%-58% lifetime risk of ovarian cancer.
- BRCA2 mutation carriers have a 13%-29% lifetime risk of ovarian cancer.
BRCA1 and BRCA2 mutations are also associated with prostate and pancreatic cancer.
Signs breast cancer may be BRCA-related
Certain patterns in your family’s health history may suggest that you or your relatives carry a BRCA1 or BRCA2 mutation linked to breast cancer.
It is possible that your family has an inherited genetic mutation linked to breast cancer if:
- You were under age 50 at diagnosis.
- You were diagnosed with triple-negative breast cancer.
- You had breast cancer in the past and were later diagnosed with a second, new breast cancer.
- You were diagnosed with breast cancer and a strong family history of breast or ovarian cancer.
A strong family history includes:
- Several relatives with breast cancer on the same side of the family
- Any relatives with ovarian cancer; 20% of ovarian cancers are associated with inherited BRCA1 and BRCA2 mutations
- A relative with both breast and ovarian cancer, or with cancer in both breasts
- Any male relative with breast cancer
- A breast or ovarian cancer diagnosis and an Ashkenazi Jewish background; about 2% of people of Ashkenazi (Central-Eastern European) descent have a BRCA mutation
Meeting with a genetic counselor can help you learn more about your personal risk of carrying a BRCA mutation. You can also discuss genetic testing options. Genetic counselors look at your personal breast cancer history as well as your family’s medical history to help guide this decision.
Visit Genetic counseling to learn more.
Who should have testing for an inherited BRCA mutation?
American Society of Clinical Oncology (ASCO) guidelines recommend testing for inherited BRCA1 and BRCA2 genetic mutations if you:
- Are 65 or younger and newly diagnosed or were treated for breast cancer in the past
- Are older than age 65 and:
- You have a personal or family history of breast cancer that suggests an inherited gene mutation, such as triple-negative breast cancer
- You are of ancestry that has a known higher incidence of inherited genetic mutations, such as Ashkenazi Jewish ancestry
- You meet eligibility requirements to take PARP inhibitor breast cancer treatment
- Have a second breast cancer diagnosis that is not a recurrence of a first breast cancer
- Have breast cancer and are assigned male at birth
Read the complete ASCO guidelines for genetic testing in people with breast cancer.
The National Comprehensive Cancer Network (NCCN) recommends BRCA testing for people diagnosed before age 50, or for people diagnosed at any age who:
- May be eligible for PARP inhibitor treatment
- Have been diagnosed with triple-negative breast cancer
- Have been diagnosed with lobular breast cancer and there is a personal or family history of a stomach cancer called diffuse gastric cancer
- Have had more than one breast cancer diagnosis
- Have been diagnosed with male breast cancer
- Are of Ashkenazi Jewish ancestry
- Have a family history that includes close blood relatives with breast cancer at age 50 or younger, male breast cancer, ovarian cancer, pancreatic cancer, or certain prostate cancers
Read the NCCN guidelines for genetic testing in people with breast cancer.
To learn more about the genetic testing process, visit Genetic testing for inherited mutations.
Testing positive for a BRCA mutation
If you’ve been diagnosed with breast cancer and tested positive for an inherited BRCA mutation, you have:
- An increased risk of breast cancer recurrence
- A higher risk of developing a second, new breast cancer
- A higher risk of developing ovarian cancer
Still, a positive result does not mean you will definitely be diagnosed with a new breast cancer or with ovarian cancer. It also does not guarantee others in your family will develop either cancer. Carrying a gene mutation does mean that you have a 50% chance of passing that mutation on to each of your children.
Learning you carry a BRCA mutation can trigger intense emotions, including fear for the future, sadness, and overwhelm. Sharing results with your family can be challenging, especially if you’re the first in your family to have genetic testing.
Visit Sharing your inherited genetic test results to learn more about talking with family, and Where to find support for additional resources.
Positive test results and treatment decisions
Breast cancer treatment decisions are based on:
- Breast cancer stage
- Biomarker test results, which include:
- Hormone receptor status
- HER2 status
- Genomic test results that measure the risk for recurrence in early-stage breast cancer and inform treatment decisions in metastatic disease
- Your overall health history
Regardless of whether you have an inherited BRCA mutation, breast cancer treatment may include:
But if you test positive for a BRCA mutation, these options may be used in different ways to not only treat the current cancer but help lower your risk of future cancers. There are also targeted therapies that are only available to people who test positive for a BRCA mutation.
Hormonal therapy, chemotherapy, immunotherapy, and targeted therapy
If you tested positive for a BRCA1 or BRCA2 mutation, your treatment may include:
- Hormonal therapy: BRCA2-related breast cancers are more likely to be estrogen receptor-positive than BRCA1-related breast cancers. These cancers are treated with hormonal therapy that blocks or reduces the estrogen that helps the cancer grow. Taking hormonal therapy for five to 10 years has been shown to reduce the risk of recurrence and second breast cancers. Learn more about hormonal therapy.
- Chemotherapy and immunotherapy: Triple-negative breast cancers are more likely to occur in women who carry a BRCA1 mutation. They are treated with chemotherapy and immunotherapy. Learn more about triple-negative breast cancer.
- PARP inhibitors: PARP inhibitors are the only targeted therapy approved specifically for people who test positive for BRCA mutations. You may be eligible for PARP inhibitor treatment if you test positive for BRCA1 or BRCA2, have HER2-negative disease, and have been treated with chemotherapy in the past. Learn more about PARP inhibitors.
Your surgical options also change with a positive BRCA test. Below, we discuss surgery options and how they can help reduce the risk of future breast cancer.
Surgery to reduce risk of recurrence or a new cancer
Surgery is part of breast cancer treatment for almost everyone. Most people diagnosed with breast cancer will have either lumpectomy or mastectomy. Depending on the timing of your genetic tests, you may already have had one of these surgeries.
People who test positive for a BRCA mutation are eligible for two additional surgery options: prophylactic mastectomy and risk-reducing salpingo-oophorectomy (ovary and fallopian tube removal).
Research shows that both options can lower the risk of future breast cancer. Oophorectomy also lowers the risk of ovarian cancer.
Still, choosing to have another surgery is a big decision and can have side effects that impact quality of life. Not everyone chooses these options.
Talk with your doctor about your individual risk level and the benefits and risks of each surgery. Your care team can work with you to decide whether additional surgery is right for you.
Risk-reducing (prophylactic) mastectomy
If you were diagnosed with breast cancer in one breast and have not yet had surgery, you have the option to have the affected breast and the healthy breast removed in a bilateral mastectomy, also called a double mastectomy. Having an unaffected breast removed with a prophylactic mastectomy means there is less breast tissue available to develop a future cancer.
If you were treated with a single mastectomy in the past and have just learned you have a BRCA mutation, talk with your doctor about the potential risk-reducing benefits of mastectomy of the other breast.
People who choose prophylactic mastectomy also have the option to get breast reconstruction.
The decision to have a healthy breast removed is very personal. Mastectomies are major surgeries and may require a good amount of rest and recovery.
Planning, undergoing, and recovering from mastectomy is also an emotional experience. For many people, it can feel overwhelming, and there can be fear, grief, or body image concerns. At the same time, reducing the risk of recurrence or a new cancer by undergoing mastectomy can sometimes bring peace of mind.
If you are considering prophylactic mastectomy, talk with your doctor about your concerns about physical and emotional recovery. Depending on your level of cancer risk, the hormonal status of the cancer, and your comfort, you may be eligible to choose to have more screening tests or to take hormonal therapy instead of undergoing mastectomy.
Risk-reducing salpingo-oophorectomy
BRCA mutations also increase the risk of ovarian cancer. Studies have shown that the ovarian cancer risk is higher in people who carry BRCA1 mutations than in those who carry BRCA2 mutations.
Having the ovaries and fallopian tubes removed in a risk-reducing salpingo-oophorectomy greatly reduces the risk of developing ovarian cancer. Many women with mutations in a BRCA1 or BRCA2 gene choose to have oophorectomy.
Oophorectomy before menopause decreases the risk of a new breast cancer. In hormone receptor-positive disease, it also stops the body from making most of its estrogen, greatly lowering the risk of breast cancer recurrence.
The risk of ovarian cancer increases with age. The National Comprehensive Cancer Network (NCCN) guidelines recommend risk-reducing salpingo-oophorectomy:
- Between ages 35 and 40 for women with BRCA1 mutations
- Between ages 40-45 for women with BRCA2 mutations
Talk with your doctor about the benefits, risks, and timing of oophorectomy before deciding. When the ovaries are removed:
- You can no longer become pregnant naturally.
- Your body goes into surgical menopause, or menopause caused by the surgery.
- Side effects can include menopausal symptoms, such as hot flashes, vaginal dryness, and bone loss.
If you plan to have children in the future, you may decide to wait until later in your life to have an oophorectomy. You can also explore options for preserving your fertility.
Testing negative for a BRCA mutation
If you test negative for a BRCA gene mutation already identified in your family, your result is considered a true negative. This result means you can usually feel confident following the standard breast cancer treatment and follow-up screening in national guidelines.
Some people test negative for BRCA mutations despite a strong personal or family history of breast and ovarian cancer. But they may still be considered high risk. If this is your experience, your doctor may suggest other family members get testing to help better clarify your risk or suggest testing for other inherited genetic mutations.
Talk with your doctor about your concerns, your family history, and what options you have for more frequent screening, risk-reducing surgery, and other measures to lower your risk of a future cancer.
To learn more about test results including variants of uncertain significance (VUS) and what test results mean for your family, visit Understanding genetic test results.
Stay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- coinsurance
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- copayments
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- deductible
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in network
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- out of network
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- preauthorization
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- premium
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical
- radiosensitization
- radiosensitizer